
    
      The first part is a single-arm, phase 1, open label, dose-escalation design in patients with
      anaplastic lymphoma kinase（ALK）/receptor tyrosine kinase（ROS1） Positive ALK/ROS1-positive
      solid tumor. The second part is an expansion in non-small cell lung Cancer (NSCLC)
      characterized by abnormalities in anaplastic lymphoma kinase(ALK) expression.
    
  